Science & Technology
Development of a Neutrophil Degranulation Inhibitor to Treat ARDS
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43HL169129-01
Award Ceiling
$306K
Award Floor
$306K
Close Date
Mar 31, 2024
Total Funding
$306K
Expected Awards
1
Posted Date
Apr 1, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R43HL169129-01
Description
SBIR Phase Phase I award: "Development of a Neutrophil Degranulation Inhibitor to Treat ARDS" awarded to DEGRANIN THERAPEUTICS, LLC in LOUISVILLE, Kentucky. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $306,424. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.